Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
548 stopped studies mapped to Malignant Nervous System Neoplasm and descendants · 90% state a reason
Over the 548 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05977322 | A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. | Phase 1 | terminated | Aug 4, 2023 | Novartis Pharmaceuticals | The decision was not based on any safety concerns | Safety / toxicity |
| NCT06359379 | Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With… | Phase 2 | terminated | Apr 11, 2024 | Shuttle Pharmaceuticals, Inc. | Terminated due to the sponsor's decision. | Sponsor / business decision |
| NCT06098248 | Evaluation of cCeLL-Ex Vivo Confocal Microscopy for Real-time Brain Tumor Diagnosis(cCeLLExvivo) | N/A | terminated | Oct 24, 2023 | VPIX Medical | Delays in specimen recruitment have increased costs and strained resources, risking study validity.… | Enrollment / accrual |
| NCT05669326 | Evaluation of the Contribution of NODDI Protocol Tractography in Brain Tumor Surgery(NODDI-TRACT) | N/A | withdrawn | Dec 30, 2022 | GCS Ramsay Santé pour l'Enseignement et la Recherche | No recrutment | Other (stated, no rule matched) |
| NCT06776406 | Head Stabilization in Whole Brain RT | N/A | withdrawn | Jan 15, 2025 | Abramson Cancer Center at Penn Medicine | Grant ended | Other (stated, no rule matched) |
| NCT03107780 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain… | Phase 1 | terminated | Apr 11, 2017 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT04657146 | Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma(LAMB-G) | — | suspended | Dec 8, 2020 | Duke University | Study undergoing amendment and funding changes. | Funding |
| NCT04209790 | Neoadjuvant Chemoradiation for Resectable Glioblastoma(NeoGlio) | Phase 2 | terminated | Dec 24, 2019 | Geisinger Clinic | Suspended to identify a permanent PI at site level. Decision to Terminate was made on 7/29/25… | Other (stated, no rule matched) |
| NCT04964960 | Pembro+Chemo in Brain Mets | Phase 2 | terminated | Jul 16, 2021 | John L. Villano, MD, PhD | Slow Accrual | Enrollment / accrual |
| NCT03904862 | Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma… | Phase 1 / Phase 2 | terminated | Apr 5, 2019 | Pediatric Brain Tumor Consortium | The decision to permanently close PBTC-053 was made following communication from the NCI that the… | Other (stated, no rule matched) |
| NCT03396575 | Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy…(BRAVO) | Phase 1 | terminated | Jan 11, 2018 | University of Florida | Not feasible to accrue due to competing studies | Enrollment / accrual |
| NCT06855628 | Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic… | Phase 2 | suspended | Mar 4, 2025 | Stanford University | low accrual | Enrollment / accrual |
| NCT04424966 | Infigratinib in Recurrent High-Grade Glioma Patients | Early Phase 1 | terminated | Jun 11, 2020 | Nader Sanai | Study drug no longer available. | Other (stated, no rule matched) |
| NCT04402073 | Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed…(PersoMed-I) | Phase 2 | terminated | May 26, 2020 | European Organisation for Research and Treatment of Cancer - EORTC | Poor accrual | Enrollment / accrual |
| NCT05341947 | Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With… | Phase 1 | withdrawn | Apr 22, 2022 | Jeremy Rudnick, M.D | Lack of Funding | Funding |
| NCT05720624 | Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation | Phase 1 | withdrawn | Feb 9, 2023 | Mayo Clinic | Funding issues | Funding |
| NCT04982926 | A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer | Phase 1 | terminated | Jul 29, 2021 | Taiho Oncology, Inc. | After careful review of Taiho's ongoing portfolio and data obtained so far in the context of… | Safety / toxicity |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3… | Early Phase 1 | terminated | Jan 15, 2021 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT05429502 | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and… | Phase 1 | terminated | Jun 23, 2022 | Novartis Pharmaceuticals | Study halted early due to high toxicity risk (from BHLRM model) in combo treatment and inability to… | Safety / toxicity |
| NCT04344652 | Photoscreening for Retinoblastoma | N/A | withdrawn | Apr 14, 2020 | Phoenix Children's Hospital | Study administratively closed at IRB prior to enrollment. | Enrollment / accrual |
| NCT02742883 | A Study of Atengenal and Astugenal in Diffuse, Intrinsic Pontine Glioma (DIPG) | Phase 2 | suspended | Apr 19, 2016 | Burzynski Research Institute | Clinical Hold | Other (stated, no rule matched) |
| NCT04023331 | 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients… | Phase 1 / Phase 2 | terminated | Jul 17, 2019 | Clarity Pharmaceuticals Ltd | Sponsor decision | Sponsor / business decision |
| NCT01849952 | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas | — | terminated | May 9, 2013 | Dartmouth-Hitchcock Medical Center | Study was administratively closed by IRB | Other (stated, no rule matched) |
| NCT03347617 | Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma | Phase 2 | terminated | Nov 20, 2017 | OHSU Knight Cancer Institute | Principal investigator transition | Investigator |
| NCT05222269 | [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients | Phase 2 | terminated | Feb 3, 2022 | Pentixapharm AG | The study was early terminated due to low patient recruitment in already activated sites and… | Enrollment / accrual |
| NCT03149575 | VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM(STAR-3) | Phase 3 | terminated | May 11, 2017 | DelMar Pharmaceuticals, Inc. | Change in clinical development plan | Other (stated, no rule matched) |
| NCT04074785 | Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or…(SCCC-06319) | Early Phase 1 | terminated | Aug 30, 2019 | University of Texas Southwestern Medical Center | Administratively closed by the IRB. | Other (stated, no rule matched) |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including… | Phase 1 / Phase 2 | terminated | Nov 6, 2017 | Alaunos Therapeutics | Sponsor decision due to slow accrual | Enrollment / accrual |
| NCT04118036 | Abemaciclib + Pembrolizumab In Glioblastoma | Phase 2 | withdrawn | Oct 7, 2019 | Dana-Farber Cancer Institute | safety concerns | Safety / toxicity |
| NCT03018288 | Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly… | Phase 2 | terminated | Jan 12, 2017 | National Cancer Institute (NCI) | Study closed early due to poor accrual. | Enrollment / accrual |
| NCT04963413 | RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly… | Phase 1 | terminated | Jul 15, 2021 | University of Florida | Terminated by mutual agreement by sponsor and institution. | Other (stated, no rule matched) |
| NCT05554159 | A Virtually Delivered Exercise Intervention To Mitigate Cognitive Deficits From… | N/A | terminated | Sep 26, 2022 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT06038760 | Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours…(PEAR-GLIO) | — | terminated | Sep 15, 2023 | Ourotech, Inc. | Lack of funding | Funding |
| NCT04729348 | Pembrolizumab And Lenvatinib In Leptomeningeal Metastases | Phase 2 | terminated | Jan 28, 2021 | Massachusetts General Hospital | Planned interim analysis | Efficacy / futility |
| NCT06501911 | A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High… | Phase 1 | withdrawn | Jul 15, 2024 | University of Nebraska | PI leaving institution. | Other (stated, no rule matched) |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | Phase 1 | terminated | Jan 23, 2020 | Actuate Therapeutics Inc. | The decision to conclude study was made to optimize the clinical study design and protocol to… | Safety / toxicity |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT04838782 | Role of Repeat Resection in Recurrent Glioblastoma | N/A | withdrawn | Apr 9, 2021 | University of Alberta | Insufficient patient population | Other (stated, no rule matched) |
| NCT03287063 | Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor… | — | terminated | Sep 19, 2017 | University of Michigan Rogel Cancer Center | Enrollment and/or interactions/interventions were halted prematurely due to loss of funding. | Enrollment / accrual |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or… | Phase 2 | terminated | Aug 28, 2020 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT04406272 | VB-111 in Surgically Accessible Recurrent/Progressive GBM | Phase 2 | terminated | May 28, 2020 | Dana-Farber Cancer Institute | Trial stopped at request of VBL Therapeutics, as they are no longer pursuing their VB-111… | Other (stated, no rule matched) |
| NCT04804709 | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive… | Phase 1 | terminated | Mar 18, 2021 | Columbia University | FDA withdrew approval of the new drug application (NDA) for panobinostat as of March 24, 2022… | Sponsor / business decision |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | — | withdrawn | Jul 10, 2024 | Mayo Clinic | Resident working with study left institution | Other (stated, no rule matched) |
| NCT00527410 | A Safety Study of RTA 744 in Recurrent, Progressive or Refractory Neoplastic Meningitis(LMD) | Phase 1 | terminated | Sep 10, 2007 | Biogen | Business Decision | Sponsor / business decision |
| NCT05297864 | PARP Inhibition for Gliomas (PI-4G or π4g)(OU-SCC-PI-4G) | Phase 2 | terminated | Mar 28, 2022 | University of Oklahoma | Funder terminated funding. | Funding |
| NCT05927610 | Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma | N/A | withdrawn | Jul 3, 2023 | Memorial Sloan Kettering Cancer Center | Recruitment has not yet been initiated | Enrollment / accrual |
| NCT05485038 | General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor…(GAMMA) | N/A | suspended | Aug 2, 2022 | Sklifosovsky Institute of Emergency Care | technical issues | Other (stated, no rule matched) |
| NCT01430351 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in… | Phase 1 | terminated | Sep 8, 2011 | M.D. Anderson Cancer Center | \<75 % participant accrual | Enrollment / accrual |
| NCT03593330 | Neurosurgical Transitional Care Programme(TCP) | N/A | terminated | Jul 20, 2018 | Barts & The London NHS Trust | Early data showed an improvement in length of stay and patient satisfaction, but the nursing time… | Other (stated, no rule matched) |
| NCT04006119 | Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With… | Phase 2 | terminated | Jul 2, 2019 | Alaunos Therapeutics | Sponsor Decision | Sponsor / business decision |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Dec 24, 2025source: clinicaltrials